RT Journal Article
SR Electronic
T1 The ongoing COVID-19 epidemic in Minas Gerais, Brazil: insights from epidemiological data and SARS-CoV-2 whole genome sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.05.20091611
DO 10.1101/2020.05.05.20091611
A1 Joilson Xavier
A1 Marta Giovanetti
A1 Talita Adelino
A1 Vagner Fonseca
A1 Alana Vitor Barbosa da Costa
A1 Adriana Aparecida Ribeiro
A1 Katlin Nascimento Felicio
A1 Clara Guerra Duarte
A1 Marcos Vinicius Ferreira Silva
A1 Álvaro Salgado
A1 Mauricio Teixeira Lima
A1 Ronaldo de Jesus
A1 Allison Fabri
A1 Cristiane Franco Soares Zoboli
A1 Thales Gutemberg Souza Santos
A1 Felipe Iani
A1 Ana Maria Bispo de Filippis
A1 Marilda Agudo Mendonça Teixeira de Siqueira
A1 André Luiz de Abreu
A1 Vasco de Azevedo
A1 Dario Brock Ramalho
A1 Carlos F. Campelo de Albuquerque
A1 Tulio de Oliveira
A1 Edward C. Holmes
A1 José Lourenço
A1 Luiz Carlos Junior Alcantara
A1 Marluce Aparecida Assunção Oliveira
YR 2020
UL http://medrxiv.org/content/early/2020/05/11/2020.05.05.20091611.abstract
AB The recent emergence of a previously unknown coronavirus (SARS-CoV-2), first confirmed in the city of Wuhan in China in December 2019, has caused serious public health and economic issues due to its rapid dissemination worldwide. Although 61,888 confirmed cases had been reported in Brazil by 28 April 2020, little was known about the SARS-CoV-2 epidemic in the country. To better understand the recent epidemic in the second most populous state in southeast Brazil (Minas Gerais, MG), we looked at existing epidemiological data from 3 states and sequenced 40 complete genomes from MG cases using Nanopore. We found evidence of multiple independent introductions from outside MG, both from genome analyses and the overly dispersed distribution of reported cases and deaths. Epidemiological estimates of the reproductive number using different data sources and theoretical assumptions all suggest a reduction in transmission potential since the first reported case, but potential for sustained transmission in the near future. The estimated date of introduction in Brazil was consistent with epidemiological data from the first case of a returning-traveler from Lombardy, Italy. These findings highlight the unique reality of MG’s epidemic and reinforce the need for real-time and continued genomic surveillance strategies as a way of understanding and therefore preparing against the epidemic spread of emerging viral pathogens.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Pan American World Health Organization (PAHO) (VPGDI-003-FIO-19-2-2-30). MG is supported by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ). V.F. and T.d.O. are supported by the South African Medical Research Council (MRC-RFA-UFSP-01-2013/UKZN HIVEPI) and the NIH H3AbioNet network, which is an initiative of the Human Health and Heredity in Africa Consortium (H3Africa). E.C.H. is supported by an Australian Research Council Australian Laureate Fellowship (FL170100022). J.L. is supported by a lectureship from the Department of Zoology, University of Oxford. J.X. and F.I is supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil (CAPES) - Finance Code 001. F.I. is also supported by Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG). A.S. has a scholarship from ZIKA-Announcement MCTIC/FNDCT-CNPq/MEC - CAPES/MS-Decit /No. 14/2016 - Prevention and Fight against Zika Virus. M.T.L. is supported by Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSARS-CoV-2 genome sequences generated in this study have been deposited in the GISAID platform (https://www.gisaid.org/), accession numbers IDs EPI_ISL_429664 to EPI_ISL_429703.